Literature DB >> 12904380

Evaluation of the Osiris expert system for identification of beta-lactam phenotypes in isolates of Pseudomonas aeruginosa.

Frédéric Bert1, Zahia Ould-Hocine, Manette Juvin, Véronique Dubois, Véronique Loncle-Provot, Valérie Lefranc, Claudine Quentin, Nicole Lambert, Guillaume Arlet.   

Abstract

Osiris is a video zone size reader for disk diffusion tests featuring a built-in extended expert system (EES). The efficacy of the EES for the identification of the beta-lactam susceptibility phenotypes of Pseudomonas aeruginosa isolates was evaluated. Thirteen beta-lactams were tested in four laboratories by the disk diffusion test with 53 strains with well-characterized resistance mechanisms, including the production of 12 extended-spectrum beta-lactamases (ESBLs). The plates were read with the Osiris system and the results were interpreted with the ESS, and then the phenotype identified by the EES was compared to the resistance mechanism. The strains were also screened for the presence of ESBL production by a double-disk synergy test by placing the strains between an extended-spectrum cephalosporin-containing disk and a clavulanic acid-containing disk at distances of 30, 20, 15, and 10 mm from each other. Overall, the EES accurately identified the phenotypes of 88.2% of the strains and indicated an association with several mechanisms for 3.8% of the strains. No phenotype was identified in four strains with low levels of penicillinase production. Misidentifications were observed for two penicillinase-producing strains: one strain with partially derepressed cephalosporinase production and one strain overexpressing the MexA-MexB-OprM efflux system. The production of only four ESBLs was detected by the standard synergy test with a 30-mm distance between the disks. The production of five further ESBLs was identified by reducing the distance to 20 mm, and the production of the last three ESBLs was detected only at a distance of 15 or 10 mm. Our results indicate that the Osiris EES is an effective tool for the identification of P. aeruginosa beta-lactam phenotypes. A specific double-disk synergy test with reduced disk distances is necessary for the detection of ESBL production by this organism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904380      PMCID: PMC179830          DOI: 10.1128/JCM.41.8.3712-3718.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa.

Authors:  L Poirel; E Ronco; T Naas; P Nordmann
Journal:  Clin Microbiol Infect       Date:  1999-10       Impact factor: 8.067

2.  Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.

Authors:  D Aubert; L Poirel; J Chevalier; S Leotard; J M Pages; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

Authors:  E Vercauteren; P Descheemaeker; M Ieven; C C Sanders; H Goossens
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

4.  Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

Authors:  F Luzzaro; E Mantengoli; M Perilli; G Lombardi; V Orlandi; A Orsatti; G Amicosante; G M Rossolini; A Toniolo
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

5.  Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended-spectrum beta-lactamases.

Authors:  H Vahaboglu; R Ozturk; H Akbal; S Saribas; O Tansel; F Coşkunkan
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

6.  OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene.

Authors:  L Poirel; D Girlich; T Naas; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

8.  Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa.

Authors:  T Naas; L Poirel; A Karim; P Nordmann
Journal:  FEMS Microbiol Lett       Date:  1999-07-15       Impact factor: 2.742

9.  OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta-lactamase from Pseudomonas aeruginosa.

Authors:  L N Philippon; T Naas; A T Bouthors; V Barakett; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

10.  Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa.

Authors:  H Yoneyama; T Nakae
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more
  3 in total

1.  Evaluation and updating of the Osiris expert system for identification of Escherichia coli beta-lactam resistance phenotypes.

Authors:  Frédéric Bert; Manette Juvin; Zahia Ould-Hocine; Gervais Clarebout; Emmanuelle Keller; Nicole Lambert; Guillaume Arlet
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 2.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Relationship between the Presence of the nalC Mutation and Multidrug Resistance in Pseudomonas aeruginosa.

Authors:  Nourkhoda Sadeghifard; Azar Valizadeh; Mohammad Reza Zolfaghary; Mohammad Hossien Maleki; Abbas Maleki; Reza Mohebi; Sobhan Ghafourian; Afra Khosravi
Journal:  Int J Microbiol       Date:  2012-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.